(Q35579008)

English

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate

scientific article published on June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

0 references

author name string

J K Buitelaar

1

1 reference

Europe PubMed Central

9 August 2017

M Casas

2

1 reference

Europe PubMed Central

9 August 2017

A Philipsen

3

1 reference

Europe PubMed Central

9 August 2017

J J S Kooij

4

1 reference

Europe PubMed Central

9 August 2017

J A Ramos-Quiroga

5

1 reference

Europe PubMed Central

9 August 2017

J Dejonckheere

6

1 reference

Europe PubMed Central

9 August 2017

J C van Oene

7

1 reference

Europe PubMed Central

9 August 2017

B Schäuble

8

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

1 June 2011

1 reference

Europe PubMed Central

9 August 2017

Psychological Medicine

1 reference

Europe PubMed Central

9 August 2017

42

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

195-204

1 reference

Europe PubMed Central

9 August 2017

Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Duloxetine in the treatment of major depressive disorder: an open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Executive functioning in adult ADHD: a meta-analytic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

A meta-analytic review of stopping performance in attention-deficit/hyperactivity disorder: deficient inhibitory motor control?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Executive dysfunction in attention-deficit/hyperactivity disorder: cognitive and neuroimaging findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Neuropsychological characteristics of adults with ADHD: a comprehensive review of initial studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

The measurement of disability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

12 July 2018

Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD?

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Functional outcomes in the treatment of adults with ADHD.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Psychometric properties of disability measures among patients with social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291711000845

21 January 2018

Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

26 September 2018

Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3226157

26 September 2018

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

https://pubmed.ncbi.nlm.nih.gov/21733214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing impairment in patients with panic disorder: the Sheehan Disability Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/21733214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention-deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21733214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1017/S0033291711000845

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35579008&oldid=1525098003"